XML 35 R19.htm IDEA: XBRL DOCUMENT

Share Capital (Tables)

3 Months Ended

Mar. 31, 2019

Share Based Compensation Allocation And Classification In Financial Statements [Abstract]

A summary of the status of the Company’s option plans as of March 31, 2019 and changes during the period then ended is presented below:

	Three months ended March 31, 2019
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		14,438,215		$	13.56
Granted		751,471			47.04
Exercised		(2,047,421	)		8.38
Forfeited and cancelled		(40,258	)		14.47
Outstanding as of March 31, 2019		13,102,007		$	16.29

Exercisable options		5,852,344		$	12.79

Schedule of RSU's

A summary of the status of the Company’s RSUs as of March 31, 2019 and changes during the period then ended is presented below:

	Three months ended March 31, 2019
	Unaudited
	Number of RSUs			Weighted average grant date fair value price
Unvested at beginning of year		1,613,197		$	14.04
Granted		486,506			47.04
Vested		(391,191	)		12.09
Forfeited and cancelled		(3,837	)		21.15
Unvested as of March 31, 2019		1,704,675		$	23.89

Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model

The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model, with the following underlying assumptions:

	Three months ended March 31,		Year ended December 31,
	2019	2018	2018
	Unaudited		Audited
Stock Option Plans
Expected term (years)	6.23	6.25	5.50-6.25
Expected volatility	55%	55%	52%-55%
Risk-free interest rate	2.40%	2.77%	2.70%-2.99%
Dividend yield	0.00%	0.00%	0.00%
ESPP
Expected term (years)	0.50	0.50	0.50
Expected volatility	62%	53%	45%-53%
Risk-free interest rate	2.51%	1.61%	1.61%-2.14%
Dividend yield	0.00%	0.00%	0.00%

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three months ended March 31, 2019 and 2018 and the year ended December 31, 2018 was:

	Three months ended March 31,				Year ended December 31,
	2019		2018		2018
	Unaudited				Audited
Cost of revenues	$	426	$	164	$	1,261
Research, development and clinical trials		1,188		906		4,709
Sales and marketing		1,962		1,436		7,393
General and administrative		6,073		6,014		26,483
Total share-based compensation expense	$	9,649	$	8,520	$	39,846